INNOVIVA, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
INNOVIVA, INC. (INVA) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-08-05
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-09-30 was 22.00K shares, a 120.00% increase year-over-year.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-06-30 was 34.00K shares.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-03-31 was 0.00 shares.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2025 was 19.00K shares.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2024 was 0.00 shares.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2023 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-05 | 0.00 shares 10-Q · filed 2026-08-05 | ||
| 2025-12-31 | 19.00K shares 10-K · filed 2026-02-25 | |||
| 2025-09-30 | 22.00K shares 10-Q · filed 2025-11-05 | 21.00K shares 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 34.00K shares 10-Q · filed 2026-08-05 | 15.00K shares 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | 0.00 shares 10-K · filed 2026-02-25 | |||
| 2024-09-30 | 10.00K shares 10-Q · filed 2025-11-05 | 0.00 shares 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 0.00 shares 10-Q · filed 2025-08-06 | 208.00K shares 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | 0.00 shares 10-K · filed 2026-02-25 | |||
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-06 | 0.00 shares 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |